ImStar Therapeutics

ImStar Therapeutics

ImStar Therapeutics is company developing treatments for ALS, dementia, and other neurodegenerative diseases.

All edits

Edits on 12 Aug, 2020
Lax Mariappan
Lax Mariappan edited on 12 Aug, 2020
Edits made to:
Infobox (+1 properties)
Infobox
Founded date
2012
Edits on 3 Aug, 2020
Marie Gabrielle Laguna- Bedia
Marie Gabrielle Laguna- Bedia edited on 3 Aug, 2020
Edits made to:
Infobox (+1 properties)
Infobox
CEO
Daniel Wattier
Edits on 30 Jul, 2020
Golden AI"Funding autocalculation"
Golden AI edited on 30 Jul, 2020
Edits made to:
Infobox (+1 properties)
Infobox
Total funding amount (USD)
1,800,000
Golden AI
Golden AI edited on 30 Jul, 2020
Edits made to:
Infobox (+1 properties)
Infobox
Funding rounds
ImStar Therapeutics Seed Funding Round June 2016
Edits on 30 Jul, 2020
Aime Anne Nisay
Aime Anne Nisay edited on 30 Jul, 2020
Edits made to:
Infobox (+1 properties)
Infobox
Edits on 4 Nov, 2019
Golden AI"Remove duplicate fields"
Golden AI edited on 4 Nov, 2019
Edits made to:
Infobox (-1 properties)
Infobox
Industry
Neuroscience
Edits on 14 Oct, 2019
Meredith Hanel
Meredith Hanel edited on 14 Oct, 2019
Edits made to:
Article (+1243/-400 characters)
Article

ImStar Therapeutics is a biotechnology company developing treatments for neurodegenerative diseases. The company is headquartered in Vancouver, British Columbia, Canada and was founded in 2012 by Daniel Wattier and Jean Pierre Julien, Professor and Senior Canada Research Chair at Université Laval. ImStar Therapeutics is developing treatments for neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS), Dementia, Alzheimer's Disease, and Parkinson's Disease.

...

ImStar Therapeutics is developing treatments for neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS), Dementia, Alzheimer's Disease, and Parkinson's Disease. The company is using its unique research findings and understanding of a protein called TAR DNA-binding protein 43 (TDP-43) and its role in inflammatory responses to develop novel treatments for neurodegenerative diseases.

Pipeline

The company is using its unique research findings and understanding of a protein called TAR DNA-binding protein 43 (TDP-43) and its role in inflammatory responses to develop novel treatments for neurodegenerative diseases. The ALS therapeutic target TDP-43, also called TANA (TDP-43 Associated NF-κB Activation) is based on the research of Dr. Julien at Université Laval.

IMS-088 was considered their lead drug development program in 2016. The compound was designed to target a key immune system activation pathway involved in neurodegeneration. IMS-088 was derived from withaferin A, a natural compound isolated from the leaves of the winter cherry plant Withania somnifera. Withaferin A in preclinical studies showed improvements in function and extended survival but lacked certain characteristics that would make it optimal for drug development. The compound IMS-088 was designed by ImStar chemists to have improved drug-like properties and to be potent and safe in preclinical studies.

Edits on 2 Jun, 2019
Will Suter
Will Suter approved a suggestion from Golden's AI on 2 Jun, 2019
Edits made to:
Article (+14/-14 characters)
Article

ImStar Therapeutics is a biotechnology company developing treatments for neurodegenerative diseases. The company is headquartered in Vancouver, British Columbia, Canada and was founded in 2012 by Daniel WattierDaniel Wattier and Jean Pierre Julien.

Edits on 29 May, 2019
Golden AI
Golden AI edited on 29 May, 2019
Edits made to:
Infobox (+1 properties)
Infobox
Founder
Daniel Wattier
Edits on 2 Apr, 2019
Dawson Sewell
Dawson Sewell edited on 2 Apr, 2019
Edits made to:
Infobox (+5 properties)
Further reading (+1 rows) (+4 cells) (+197 characters)
Further reading

Title
Author
Link
Type

ImStar Therapeutics raises $1.8 million to research ALS treatment solutions | BetaKit

JESSICA GALANG

Web

Infobox
Location
British Columbia
Industry
Therapeutics
Date incorporated
2012
Edits on 21 Jan, 2019
Golden AI"Changed markets to industries"
Golden AI edited on 21 Jan, 2019
Edits made to:
Infobox (+2/-2 properties)
Infobox
Market
Neuroscience
Industry
Neuroscience
Edits on 9 Jan, 2019
Golden AI
Golden AI edited on 9 Jan, 2019
Edits made to:
Infobox (+1 properties)
Infobox
Is a
Company
Edits on 14 Dec, 2018
Jude Gomila
Jude Gomila approved a suggestion from Golden's AI on 14 Dec, 2018
Edits made to:
Article (+16/-16 characters)
Article

ImStar Therapeutics is a biotechnology company developing treatments for neurodegenerative diseases. The company is headquartered in Vancouver, British ColumbiaBritish Columbia, Canada and was founded in 2012 by Daniel Wattier and Jean Pierre Julien.

Edits on 12 Dec, 2018
Golden AI"Import data"
Golden AI edited on 12 Dec, 2018
Edits made to:
Infobox (+2 properties)
Categories (+1 topics)
Infobox
Market
Biotechnology
Categories
Edits on 9 Dec, 2018
Jude Gomila
Jude Gomila approved a suggestion from Golden's AI on 9 Dec, 2018
Edits made to:
Article (+29/-29 characters)
Article

ImStar Therapeutics is developing treatments for neurodegenerative diseases such as Amyotrophic Lateral SclerosisAmyotrophic Lateral Sclerosis (ALS), Dementia, Alzheimer's Disease, and Parkinson's Disease. The company is using its unique research findings and understanding of a protein called TAR DNA-binding protein 43 (TDP-43) and its role in inflammatory responses to develop novel treatments for neurodegenerative diseases.

Edits on 8 Dec, 2018
Dawson Sewell
Dawson Sewell approved a suggestion from Golden's AI on 8 Dec, 2018
Edits made to:
Article (+6/-6 characters)
Article

ImStar Therapeutics is a biotechnology company developing treatments for neurodegenerative diseases. The company is headquartered in Vancouver, British Columbia, CanadaCanada and was founded in 2012 by Daniel Wattier and Jean Pierre Julien.

Dawson Sewell
Dawson Sewell approved a suggestion from Golden's AI on 8 Dec, 2018
Edits made to:
Article (+9/-9 characters)
Article

ImStar Therapeutics is a biotechnology company developing treatments for neurodegenerative diseases. The company is headquartered in VancouverVancouver, British Columbia, Canada and was founded in 2012 by Daniel Wattier and Jean Pierre Julien.

Dawson Sewell
Dawson Sewell approved a suggestion from Golden's AI on 8 Dec, 2018
Edits made to:
Article (+8/-8 characters)
Article

ImStar Therapeutics is developing treatments for neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS), DementiaDementia, Alzheimer's Disease, and Parkinson's Disease. The company is using its unique research findings and understanding of a protein called TAR DNA-binding protein 43 (TDP-43) and its role in inflammatory responses to develop novel treatments for neurodegenerative diseases.

Edits on 1 Dec, 2018
Dawson Sewell
Dawson Sewell edited on 1 Dec, 2018
Edits made to:
Infobox (+2 properties)
Description (+109/-54 characters)
Article (+817 characters)
People (+5 rows) (+10 cells) (+165/-7 characters)
Further reading (+2 rows) (+8 cells) (+429 characters)
Categories (+1 topics)
Topic thumbnail

ImStar Therapeutics

A company transforming ALS & Neurodegenerative Disease

ImStar Therapeutics is company developing treatments for ALS, dementia, and other neurodegenerative diseases.

Article

ImStar Therapeutics is a biotechnology company developing treatments for neurodegenerative diseases. The company is headquartered in Vancouver, British Columbia, Canada and was founded in 2012 by Daniel Wattier and Jean Pierre Julien.

ImStar Therapeutics is developing treatments for neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS), Dementia, Alzheimer's Disease, and Parkinson's Disease. The company is using its unique research findings and understanding of a protein called TAR DNA-binding protein 43 (TDP-43) and its role in inflammatory responses to develop novel treatments for neurodegenerative diseases.

Funding

Seed Round

On June 8, 2016 ImStar Therapeutics closed their seed funding round with $1.8 million in funding from BDC Venture Capital and Accel-Rx Health Sciences Accelerator.

People

Name
Role
Related Golden topics

Agnes Chan

COO

Daniel Wattier

FounderCo-Founder & CEO

David Hunt

Senior Vice President, Research and Development

Jean Pierre Julien

Co-Founder & CSO

Jeff Charpentier

CFO

Julia Levy

Board Chair

Further reading

Title
Author
Link
Type

ImStar Therapeutics Selects Lead Drug Candidate for ALS

ImStar Therapeutics

News

StemCells, Inc. Appoints Ian Massey as President and Chief Operating Officer

StemCells, Inc.

Web

Infobox
Categories
Edits on 19 Jul, 2018
Golden AI"Update locations in infobox"
Golden AI edited on 19 Jul, 2018
Infobox
Location
Vancouver
Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.